An estimated 22.2 million Brazilians suffer from chronic pain in the lower back and neck.
Were Brazil to legalize medical cannabis, within the first 36 months of sales the number of qualified patients could reach 959,000 under a restrictive list of qualifying conditions (i.e., not including chronic pain), or roughly 3.4 million under an expansive list of conditions (covering chronic pain).
An expansive program featuring chronic pain as a qualifying condition and patient counts of 3.4 million patients would translate to annual revenues of roughly BRL4.4 billion (USD 1.4 billion).
